Outlook Therapeutics Q4 2024 Earnings Report $1.56 -0.08 (-4.88%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Outlook Therapeutics EPS ResultsActual EPS-$0.77Consensus EPS -$0.83Beat/MissBeat by +$0.06One Year Ago EPSN/AOutlook Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOutlook Therapeutics Announcement DetailsQuarterQ4 2024Date12/27/2024TimeBefore Market OpensConference Call ResourcesOTLK Earnings History Outlook Therapeutics Earnings HeadlinesHC Wainwright Has Negative Forecast for OTLK Q2 EarningsFebruary 22 at 2:26 AM | americanbankingnews.comWhat is HC Wainwright's Forecast for OTLK Q1 Earnings?February 21 at 2:57 AM | americanbankingnews.comGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. February 22, 2025 | Crypto 101 Media (Ad)Outlook Therapeutics (NASDAQ:OTLK) Price Target Cut to $3.00 by Analysts at HC WainwrightFebruary 20 at 2:31 AM | americanbankingnews.comOutlook Therapeutics (NASDAQ:OTLK) Given "Neutral" Rating at Chardan CapitalFebruary 20 at 2:31 AM | americanbankingnews.comOutlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19 at 9:00 AM | globenewswire.comSee More Outlook Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Outlook Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Outlook Therapeutics and other key companies, straight to your email. Email Address About Outlook TherapeuticsOutlook Therapeutics (NASDAQ:OTLK), operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.View Outlook Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
